Frequently Asked Questions: Avid Weight Program
Weight loss medications like Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription treatments designed to support individuals in achieving significant weight loss by reducing appetite and controlling hunger.
Mounjaro and Wegovy are self-administered through pre-filled injectable pens. These pens are designed for easy, once-weekly use, and detailed instructions are provided to ensure safe and correct administration. Our team is also available to guide you if you need additional support.
Mounjaro and Wegovy mimic naturally occurring hormones to regulate appetite and digestion, helping to maek you feel fuller for longer, reduce your calorie intake and promote effective weight loss.
Yes, both medications have undergone rigorous clinical trials and are fully approved for use in the UK. When accessing these medications through Avid, a qualified healthcare provider will evaluate your medical history to ensure they are safe for you. It is important to only obtain this medication through fully regulated and approved clinical organisations and established pharmacies.
These medications are currently available on the NHS for certain cohorts of patients. More information here:
They are typically prescribed for adults with a BMI over 30 or over 27 if they have weight-related health conditions, such as type 2 diabetes or high blood pressure.
Your eligibility depends on your overall health and specific conditions. Your Avid Clinician and prescribing pharmacist will make sure the medication is safe and appropriate for you before prescribing.
Yes, these medications require a prescription from a qualified healthcare professional. It is important that you only take these medications with guidance and oversight from a qualified healthcare professional to make sure they are safe for you. Avid's Clinicians and prescribing pharmacists are able to provide this service in a fully regulated and quality clinical setting to ensure you get the best outcome.
Clinical trials show that patients can lose 15-20% of their body weight with Wegovy and up to 22.5% with Mounjaro when combined with a healthy diet and exercise.
References:
Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11):989-1002. DOI: 10.1056/NEJMoa2032183
Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. JAMA, 327(14):1345–1356. DOI: 10.1001/jama.2022.3228
These medications are safe when prescribed appropriately with the correct clinical guidance. Common side effects may include nausea, vomiting, diarrhoea, and constipation. These typically decrease over time as your body adjusts to the medication. Your Avid Team will be able to provide more information on these and support you in managing and reducing their impact.